Compare · MPLT vs MRK
MPLT vs MRK
Side-by-side comparison of MapLight Therapeutics Inc. (MPLT) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MPLT and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $311.84B, about 183.7x MPLT ($1.70B).
- Over the past year, MPLT is up 105.3% and MRK is up 54.7% - MPLT leads by 50.7 points.
- MPLT has been more active in the news (11 items in the past 4 weeks vs 8 for MRK).
- MRK has more recent analyst coverage (25 ratings vs 12 for MPLT).
- Company
- MapLight Therapeutics Inc.
- Merck & Company Inc.
- Price
- $37.51+4.04%
- $126.26+1.50%
- Market cap
- $1.70B
- $311.84B
- 1M return
- +30.13%
- +10.86%
- 1Y return
- +105.31%
- +54.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 11
- 8
- Recent ratings
- 12
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest MPLT
- BMO Capital Markets initiated coverage on MapLight Therapeutics with a new price target
- Chief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax
- CAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Kroeger Christopher A. sold $5,443,722 worth of Voting Common Stock (147,639 units at $36.87), decreasing direct ownership by 11% to 1,246,455 units (SEC Form 4) to satisfy withholding obligation
- Chief Scientific Officer Lillie James Woodruff sold $673,636 worth of Voting Common Stock (18,267 units at $36.88), decreasing direct ownership by 8% to 224,462 units (SEC Form 4) to satisfy withholding obligation
- General Counsel Hanson Kristopher sold $607,870 worth of Voting Common Stock (16,508 units at $36.82), decreasing direct ownership by 10% to 145,823 units (SEC Form 4) to cover taxes
- Chief Medical Officer Foff Erin Pennock sold $1,734,490 worth of Voting Common Stock (47,158 units at $36.78) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 298,901 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.